A Phase III trial of AVONEX® (Inteferon beta-1a) was conducted in people with secondary progressive multiple sclerosis. The Company has filed for expanded indication in Europe and in Canada based on results from this study.
Terms and Conditions of Use // Copyright © BIOGEN. Designed by Foster Design Group, Inc., and created and maintained by embarc. // Note Regarding Forward Looking Statements // Privacy Policy
